Stockscreener 앱 받기
20.59
1.03%
0.21
전일 마감가:
$20.38
열려 있는:
$20.44
하루 거래량:
814.35K
Relative Volume:
0.60
시가총액:
$2.52B
수익:
$460.48M
순이익/손실:
$142.80M
주가수익비율:
17.45
EPS:
1.18
순현금흐름:
$221.79M
1주 성능:
-2.32%
1개월 성능:
-2.02%
6개월 성능:
-4.94%
1년 성능:
+3.05%
1일 변동 폭
$20.39
$20.66
1주일 범위
$19.83
$21.82
52주 변동 폭
$19.00
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
명칭
Catalyst Pharmaceuticals Inc
전화
(305) 529-2522
주소
355 ALHAMBRA CIRCLE, CORAL GABLES
CPRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
20.59 | 2.49B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-04 | 개시 | Robert W. Baird | Outperform |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-03-14 | 개시 | Citigroup | Buy |
| 2024-03-07 | 개시 | BofA Securities | Buy |
| 2023-12-21 | 개시 | Oppenheimer | Outperform |
| 2022-08-24 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-07 | 재개 | Piper Jaffray | Overweight |
| 2016-10-05 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | 재확인 | ROTH Capital | Buy |
| 2014-09-16 | 재확인 | ROTH Capital | Buy |
| 2014-09-15 | 재확인 | H.C. Wainwright | Buy |
| 2013-10-21 | 재확인 | Aegis Capital | Buy |
| 2013-09-24 | 개시 | Maxim Group | Buy |
| 2013-09-06 | 재확인 | Aegis Capital | Buy |
| 2013-04-18 | 개시 | Aegis Capital | Buy |
| 2012-08-27 | 업그레이드 | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | 업그레이드 | Merriman | Sell → Neutral |
| 2009-05-29 | 다운그레이드 | Hapoalim | Neutral → Underperform |
| 2009-05-29 | 다운그레이드 | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | 개시 | Merriman Curhan Ford | Buy |
| 2007-11-28 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | 개시 | Stifel Nicolaus | Buy |
| 2007-01-05 | 개시 | First Albany | Buy |
모두보기
Catalyst Pharmaceuticals Inc 주식(CPRX)의 최신 뉴스
Does Catalyst Pharmaceuticals Inc. have pricing powerJuly 2025 Drop Watch & High Accuracy Swing Entry Alerts - خودرو بانک
Using data models to predict Catalyst Pharmaceuticals Inc. stock movementWeekly Loss Report & Free Low Drawdown Momentum Trade Ideas - Newser
Should you wait for a breakout in Catalyst Pharmaceuticals Inc.Oil Prices & AI Forecast Swing Trade Picks - Newser
News impact scoring models applied to Catalyst Pharmaceuticals Inc.Bull Run & Risk Controlled Stock Pick Alerts - Newser
Detecting support and resistance levels for Catalyst Pharmaceuticals Inc.July 2025 Price Swings & Daily Chart Pattern Signal Reports - Newser
Statistical indicators supporting Catalyst Pharmaceuticals Inc.’s strengthPortfolio Growth Summary & Low Drawdown Trading Techniques - Newser
Market reaction to Catalyst Pharmaceuticals Inc.’s recent newsBreakout Watch & Real-Time Buy Signal Alerts - Newser
Is Catalyst Pharmaceuticals Inc. building a consolidation baseJuly 2025 Review & Technical Buy Zone Confirmation - Newser
Will Catalyst Pharmaceuticals Inc. price bounce be sustainableGap Up & Growth Focused Stock Reports - Newser
How to monitor Catalyst Pharmaceuticals Inc. with trend dashboards2025 Market Sentiment & Free High Accuracy Swing Entry Alerts - Newser
Published on: 2025-08-30 22:54:38 - beatles.ru
Short Interest Drops in Catalyst Pharmaceuticals Inc. After RallyJuly 2025 Sentiment & Safe Capital Growth Stock Tips - beatles.ru
Catalyst Pharmaceuticals Secures Exclusivity for FIRDAPSE Until 2035 - AInvest
Catalyst Pharmaceuticals Inc. stock trendline breakdownMarket Rally & Weekly Top Stock Performers List - Newser
Risk vs reward if holding onto Catalyst Pharmaceuticals Inc.Earnings Trend Report & Free Low Drawdown Momentum Trade Ideas - Newser
Identifying reversal signals in Catalyst Pharmaceuticals Inc.July 2025 Levels & Low Risk Entry Point Guides - Newser
What is Catalyst Pharmaceuticals Inc. s 5 year growth outlookTrade Risk Assessment & Daily Stock Momentum Reports - sundaytimes.kr
Catalyst Pharmaceuticals Inc. stock prediction for this weekTrade Analysis Report & Momentum Based Trading Ideas - Newser
Strategies to average down on Catalyst Pharmaceuticals Inc.Weekly Profit Recap & AI Driven Price Forecasts - Newser
Should you hold or exit Catalyst Pharmaceuticals Inc. nowJobs Report & AI Forecast Swing Trade Picks - Newser
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
How to recover losses in Catalyst Pharmaceuticals Inc. stockPortfolio Update Summary & Free Fast Gain Swing Trade Alerts - Newser
Heatmap analysis for Catalyst Pharmaceuticals Inc. and competitors2025 Price Momentum & Short-Term Swing Trade Alerts - Newser
Catalyst Pharmaceuticals CEO Richard Daly Trades $473K in Company Stock - AInvest
Catalyst Pharmaceutical (CPRX) is a Strong Value Stock - AInvest
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock - Yahoo Finance
Catalyst Pharmaceuticals, Inc. (CPRX) Secures FIRDAPSE Market Exclusivity Until 2035 - Insider Monkey
Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y - MSN
Risk adjusted return profile for Catalyst Pharmaceuticals Inc. analyzedTrade Ideas & Real-Time Chart Breakout Alerts - Newser
Catalyst Pharmaceuticals Inc (CPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Catalyst Pharmaceuticals Inc 주식 (CPRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Tierney David S | Director |
Aug 27 '25 |
Sale |
20.20 |
26,000 |
525,200 |
379,620 |
| Miller Steve | Chief Op. & Scientific Officer |
Aug 26 '25 |
Option Exercise |
2.24 |
115,000 |
257,600 |
1,064,663 |
| Miller Steve | Chief Op. & Scientific Officer |
Aug 27 '25 |
Option Exercise |
2.24 |
110,000 |
246,400 |
1,059,663 |
| Miller Steve | Chief Op. & Scientific Officer |
Aug 26 '25 |
Sale |
20.28 |
115,000 |
2,332,200 |
949,663 |
| Daly Richard J | President and CEO |
Aug 26 '25 |
Option Exercise |
2.24 |
50,000 |
112,000 |
249,764 |
| Daly Richard J | President and CEO |
Aug 26 '25 |
Sale |
20.62 |
22,970 |
473,641 |
226,794 |
0.96%
1.09%
자본화:
|
볼륨(24시간):